S. Hancock

Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS.

D. Wallace, V. Desquiret-Dumas, D. Bonneau, 2012, Biochimica et biophysica acta.

The mitochondrial adenine nucleotide transporters in myogenesis.

D. Wallace, P. Coskun, A. Flierl, 2022, Free radical biology & medicine.

Essential role of mitochondrial energy metabolism in Foxp3+ T‐regulatory cell function and allograft survival

D. Wallace, J. Baur, U. Beier, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease.

D. Wallace, D. Mishmar, E. Ruiz-Pesini, 2009, Molecular genetics and metabolism.

Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming

Vincent Procaccio, Martin Picard, Shawn Levy, 2014, Proceedings of the National Academy of Sciences.

Differential NF-kappaB and IkappaB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance.

L. Turka, W. Hancock, V. Csizmadia, 2001, Transplantation.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

M. Erlander, A. Bardelli, F. Meric-Bernstam, 2017, Clinical Cancer Research.

Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.

M. Erlander, S. Lippman, R. Kurzrock, 2015 .

Mutations of Human NARS2, Encoding the Mitochondrial Asparaginyl-tRNA Synthetase, Cause Nonsyndromic Deafness and Leigh Syndrome

A. Starr, A. Busch, Eddie Park, 2015, PLoS genetics.

Title Mutations of Human NARS 2 , Encoding the Mitochondrial Asparaginyl-tRNA Synthetase , Cause Nonsyndromic Deafness and Leigh Syndrome Permalink

A. Starr, A. Busch, Eddie Park, 2015 .

Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations.

M. Erlander, J. Poole, L. Benesova, 2015 .